Traders should monitor upcoming regulatory milestones, including EMA review timelines and potential approval in 2027. Positive data presentation at a medical congress in 2026 could serve as a near-term catalyst. Consider positioning ahead of potential commercial launch in Europe.
Price Chart
Executive Summary
GSK announced that the European Medicines Agency (EMA) has accepted for review its marketing application for bepirovirsen, an investigational first-in-class treatment for chronic hepatitis B. The submission is supported by positive Phase III trial results showing statistically significant and clinically meaningful functional cure rates compared to current standard of care.
Key Facts
- EMA has accepted for review the marketing authorisation application (MAA) for bepirovirsen for the treatment of chronic hepatitis B (CHB).
- The submission is based on positive results from two pivotal Phase III trials (B-Well 1 and B-Well 2), which met their primary endpoints with statistically significant functional cure rates.
- Functional cure rates were significantly higher with bepirovirsen plus standard of care versus standard of care alone, especially in patients with baseline HBsAg ≤1000 IU/ml.
- An estimated 3.2 million people in Europe live with CHB, and current treatments have functional cure rates of only ~1%, highlighting the significant unmet medical need.
- Bepirovirsen is a first-in-class antisense oligonucleotide licensed from Ionis Pharmaceuticals and is not yet approved anywhere globally.
Financial Impact
High potential revenue upside if approved, given large addressable market (~3.2M patients in Europe) and lack of effective curative therapies. Could position bepirovirsen as a blockbuster asset in hepatology.
Risk Factors
- Regulatory approval is not guaranteed despite acceptance for review.
- Safety or efficacy concerns could emerge during the review process or in future real-world use.
- Commercial uptake may be limited by pricing, reimbursement, or competition from other emerging therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-002848 |
| Document: 0001654954-26-002848-index-headers.html | 0001654954-26-002848 |
| Document: 0001654954-26-002848-index.html | 0001654954-26-002848 |
| Document: 0001654954-26-002848.txt | 0001654954-26-002848 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $25.12 $25.25 | ▲ +0.52% | ▼ −1.62% | $26.12 (+3.98%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
May 28, 2026 21w ago | 6-K | $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.12 (+6.27%) |
May 27, 2026 21w ago | 6-K | $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.12 (+2.15%) |
May 26, 2026 22w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 26, 2026 22w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 22, 2026 22w ago | 6-K | $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.12 (+0.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers